Steenbergen, Renske D. M.
Snijders, Peter J. F.
Heideman, Daniƫlle A. M.
Meijer, Chris J. L. M.
Article History
First Online: 23 May 2014
Competing interests
: C.J.L.M.M. has been a member of the scientific advisory board of Qiagen, has received speaker's fees from GlaxoSmithKline, Merck, and Roche and his institution has received board membership and consultancy fees from Qiagen. P.J.F.S. has received speaker's fees from Roche, Abbott, Qiagen, and Gen-Probe. P.J.F.S. and C.J.L.M.M. hold a patent for HPV detection by GP5+/6+ PCR through Qiagen, for which their institution has received honoraria. C.J.L.M.M., R.D.M.S., and P.J.F.S. hold a patent for promoter methylation of CADM1 as a specific marker for CIN grade 2 or 3 or cervical cancer through MdxHealth, for which their institution received honoraria. C.J.L.M.M., P.J.F.S., R.D.M.S., and D.A.M.H. are shareholders of Self-screen.